Cargando…
Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation
BACKGROUND: The safety of pharmacotherapy in atrial fibrillation (AF) is compounded by a trilogy of risks old age, high-risk medications (e.g., antithrombotics, antiarrhythmics), polypharmacy due to multiple patient comorbidities. However, to date, scarce study has investigated the use of polypharma...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930859/ https://www.ncbi.nlm.nih.gov/pubmed/27382425 http://dx.doi.org/10.18549/PharmPract.2016.02.706 |
_version_ | 1782440798330028032 |
---|---|
author | Wang., Yishen Singh., Shamsher Bajorek., Beata |
author_facet | Wang., Yishen Singh., Shamsher Bajorek., Beata |
author_sort | Wang., Yishen |
collection | PubMed |
description | BACKGROUND: The safety of pharmacotherapy in atrial fibrillation (AF) is compounded by a trilogy of risks old age, high-risk medications (e.g., antithrombotics, antiarrhythmics), polypharmacy due to multiple patient comorbidities. However, to date, scarce study has investigated the use of polypharmacy (including potentially inappropriate medication (PIM)) in AF patients, and how this may contribute to their overall risk of medication misadventure. OBJECTIVES: To review the extent of polypharmacy and PIM use in older patients (65 years or older) with AF. METHODS: Information was extracted from a database characterising a cohort of older AF patients treated in general practice in New South Wales, Australia. Patient characteristics, number and types of drugs, the degree of PIM use were recorded. The predictors for the use of polypharmacy in older AF patients were identified. RESULTS: Overall, 367 patients (mean age 77.8 years) were reviewed, among which 94.8% used 5 medications or more and over half used 10 medications or more. Cardiovascular agents were most commonly used (98.9%), followed by antithrombotics (90.7%). Among agents deemed PIMs, digoxin (30.2%) was the most frequently used, followed by benzodiazepines (19.6%), and sotalol (9.8%). AF patients using polypharmacy were more likely to have low bleeding risk (OR=10.97), representing those patients in whom high-risk antithrombotics are mostly indicated. Patients with major-polypharmacy (5-9 medications) are more likely to have obstructive pulmonary diseases (OR=2.32), upper gastrointestinal diseases (OR=2.02) and poor physical function (OR=1.04), but less likely to have cognitive impairment (OR=0.27). CONCLUSION: Polypharmacy affects oldest AF patients, comprising medications that are indicated for AF, yet regarded as PIMs. Patients with lower risk of bleeding, obstructive pulmonary diseases, upper gastrointestinal diseases and poor physical function are also at higher risk of using higher number of medications. This may lead to an increased risk for medication misadventure due to the concomitant use of polypharmacy and medications for AF. |
format | Online Article Text |
id | pubmed-4930859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Centro de Investigaciones y Publicaciones Farmaceuticas |
record_format | MEDLINE/PubMed |
spelling | pubmed-49308592016-07-05 Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation Wang., Yishen Singh., Shamsher Bajorek., Beata Pharm Pract (Granada) Original Research BACKGROUND: The safety of pharmacotherapy in atrial fibrillation (AF) is compounded by a trilogy of risks old age, high-risk medications (e.g., antithrombotics, antiarrhythmics), polypharmacy due to multiple patient comorbidities. However, to date, scarce study has investigated the use of polypharmacy (including potentially inappropriate medication (PIM)) in AF patients, and how this may contribute to their overall risk of medication misadventure. OBJECTIVES: To review the extent of polypharmacy and PIM use in older patients (65 years or older) with AF. METHODS: Information was extracted from a database characterising a cohort of older AF patients treated in general practice in New South Wales, Australia. Patient characteristics, number and types of drugs, the degree of PIM use were recorded. The predictors for the use of polypharmacy in older AF patients were identified. RESULTS: Overall, 367 patients (mean age 77.8 years) were reviewed, among which 94.8% used 5 medications or more and over half used 10 medications or more. Cardiovascular agents were most commonly used (98.9%), followed by antithrombotics (90.7%). Among agents deemed PIMs, digoxin (30.2%) was the most frequently used, followed by benzodiazepines (19.6%), and sotalol (9.8%). AF patients using polypharmacy were more likely to have low bleeding risk (OR=10.97), representing those patients in whom high-risk antithrombotics are mostly indicated. Patients with major-polypharmacy (5-9 medications) are more likely to have obstructive pulmonary diseases (OR=2.32), upper gastrointestinal diseases (OR=2.02) and poor physical function (OR=1.04), but less likely to have cognitive impairment (OR=0.27). CONCLUSION: Polypharmacy affects oldest AF patients, comprising medications that are indicated for AF, yet regarded as PIMs. Patients with lower risk of bleeding, obstructive pulmonary diseases, upper gastrointestinal diseases and poor physical function are also at higher risk of using higher number of medications. This may lead to an increased risk for medication misadventure due to the concomitant use of polypharmacy and medications for AF. Centro de Investigaciones y Publicaciones Farmaceuticas 2016 2016-06-15 /pmc/articles/PMC4930859/ /pubmed/27382425 http://dx.doi.org/10.18549/PharmPract.2016.02.706 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Wang., Yishen Singh., Shamsher Bajorek., Beata Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation |
title | Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation |
title_full | Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation |
title_fullStr | Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation |
title_full_unstemmed | Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation |
title_short | Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation |
title_sort | old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930859/ https://www.ncbi.nlm.nih.gov/pubmed/27382425 http://dx.doi.org/10.18549/PharmPract.2016.02.706 |
work_keys_str_mv | AT wangyishen oldagehighriskmedicationpolypharmacyatrilogyofrisksinolderpatientswithatrialfibrillation AT singhshamsher oldagehighriskmedicationpolypharmacyatrilogyofrisksinolderpatientswithatrialfibrillation AT bajorekbeata oldagehighriskmedicationpolypharmacyatrilogyofrisksinolderpatientswithatrialfibrillation |